共 50 条
- [31] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerJOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +Wirth, Lori J.Brose, Marcia S.Sherman, Eric J.Licitra, LisaSchlumberger, MartinSherman, Steven, IBible, Keith C.Robinson, BruceRodien, PatriceGodbert, YannDe La Fouchardiere, ChristelleNewbold, KateNutting, ChristopherMisir, SoamnauthXie, RanAlmonte, AnaYe, WeifeiCabanillas, Maria E.
- [32] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091Guo, HonghaiDing, Ping'anYang, PeigangTian, YuanLiu, YangZhang, ZeZheng, TaoZhang, ZhidongWang, DongTan, BiboZhao, XuefengLi, YongZhao, Qun
- [33] Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical studyIMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (07)Onodera, MasafumiUchiyama, ToruAriga, TadashiYamada, MasafumiMiyamura, TakakoArizono, HironoriMorio, Tomohiro
- [34] A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)BLOOD, 2020, 136Zhang, FengkuiPeng, GuangxinHe, GuangshengChang, HongGao, SujunLiu, XinjianChen, TongLi, PeiHan, BingMiao, MiaoGe, ZhengGe, XiaoyanLi, FeiLi, YingmeiWang, ShunqingWang, YiShen, YaqiTai, YanfeiZhang, TaoZhu, BoZou, Jianjun
- [35] Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 studyANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)Mei, HengChen, XiequnZhou, JianfengLuo, JianminShi, QingzhiLiu, JingWu, DepeiChen, GuoanTai, YanfeiXiong, JunyeZou, JianjunHu, Yu
- [36] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II studyANNALS OF ONCOLOGY, 2021, 32 : S734 - S734Chen, J.Wei, W.Zheng, L.Li, H.Feng, Y.Wan, T.Huang, Q.Liu, G.Tu, H.Qiu, J.Jiang, X.Xiong, Y.Zheng, M.Li, J.Huang, H.Song, L.Liu, J.Zhang, Y.
- [37] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical TrialTargeted Oncology, 2019, 14 : 541 - 550Ali A. MokdadHao ZhuMuhammad S. BegYull ArriagaJonathan E. DowellAmit G. SingalAdam C. Yopp
- [38] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical TrialTARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550Mokdad, Ali A.Zhu, HaoBeg, Muhammad S.Arriaga, YullDowell, Jonathan E.Singal, Amit G.Yopp, Adam C.
- [39] Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/IIINTERNATIONAL JOURNAL OF SURGERY PROTOCOLS, 2024, 28 (01): : 1 - 5Namba, YosukeKobayashi, TsuyoshiKuroda, ShintaroHashimoto, MasakazuTakei, DaisukeFukuhara, SotaroOshita, KoMatsubara, KeisoHonmyo, NaruhikoNakano, RyosukeSakai, HiroshiTahara, HiroyukiOhira, MasahiroIde, KentaroOhdan, Hideki
- [40] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Mao, LiliDai, JieBai, XueKong, YanSheng, XinanChi, ZhihongCui, ChuanliangLian, BinTang, BixiaYan, XieqiaoWang, XuanLi, SimingZhou, LiWei, XiaotingLi, JuanLi, CailiDuan, RongXu, HuayanGuo, JunSi, Lu